The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Accumulation of active metabolite M-2 predicts overall survival (OS) of chemorefractory metastatic colorectal cancer patients treated with regorafenib (REGO).
 
Benoit Rousseau
Consulting or Advisory Role - Bayer (Inst); Roche (Inst)
Speakers' Bureau - Bayer; Gilead Sciences
Research Funding - Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - Astellas Pharma; Bayer; SERVIER
 
Arezki Khaled Boukerma
No Relationships to Disclose
 
Julie Henriques
No Relationships to Disclose
 
Romain Cohen
Consulting or Advisory Role - Amgen; Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Olivier Lucidarme
No Relationships to Disclose
 
Christophe Borg
No Relationships to Disclose
 
Christophe Tournigand
Honoraria - Bayer; Bristol-Myers Squibb; MSD; Roche; Sanofi
Consulting or Advisory Role - Bayer
Research Funding - Roche
Travel, Accommodations, Expenses - Bayer; MSD; Roche
 
Stefano Chong Hun Kim
No Relationships to Disclose
 
Jean-Baptiste Bachet
No Relationships to Disclose
 
Thibault Mazard
No Relationships to Disclose
 
Christophe Louvet
Consulting or Advisory Role - Halozyme
Travel, Accommodations, Expenses - Roche
 
Benoist Chibaudel
No Relationships to Disclose
 
Luis A. Diaz
Leadership - Jounce Therapeutics; Personal Genome Diagnostics
Stock and Other Ownership Interests - Jounce Therapeutics; PapGene, Inc.; Personal Genome Diagnostics; Zydecom
Consulting or Advisory Role - Caris Life Sciences; Cell Design Labs; Genocea Biosciences; Lyndra Therapeutics; Merck; Personal Genome Diagnostics; Phoremost; Zydecom
Research Funding - Merck (Inst)
Patents, Royalties, Other Intellectual Property - EP-2912468-B1 - Papanicolaou test for ovarian and endometrial cancers; EP-3322824-A1 - Detection of tumor-derived dna in cerebrospinal fluid; US-2005202465-A1 - Thymidylate synthase gene and metastasis; US-2010041048-A1 - Circulating Mutant DNA to Assess Tumor Dynamics; US-2013323167-A1 - Detecting and treating solid tumors through selective disruption of tumor vasculature; US-2014227271-A1 - Somatic mutations in atrx in brain cancer; US-2015252415-A1 - Arid1b and neuroblastoma; US-2015344970-A1 - Personalized Tumor Biomarkers; US-2016208340-A1 - TERT Promoter Mutations in Urothelial Neoplasia; US-2016273049-A1 - Systems and methods for analyzing nucleic acid (Inst); US-2017016075-A1 - Neoantigen analysis (Inst); US-2017267760-A1 - Checkpoint Blockade and Microsatellite Instability; US-2018086832-A1 - Hla-restricted epitopes encoded by somatically mutated genes; US-2018135044-A1 - Non-unique barcodes in a genotyping assay (Inst); US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018171413-A1 - Head and neck squamous cell carcinoma assays; US-2018258490-A1 - Assaying ovarian cyst fluid; US-9976184-B2 - Mutations in pancreatic neoplasms; WO-2010118016-A2 - Digital quantification of dna methylation; WO-2012094401-A2 - Genes frequently altered in pancreatic neuroendocrine tumors; WO-2018071796-A2 - Compositions and methods for identifying functional anti-tumor t cell responses
Travel, Accommodations, Expenses - Merck
 
Dewi Vernerey
No Relationships to Disclose
 
Thierry Andre
Honoraria - AMGEN; Bayer; Bristol-Myers Squibb; PRMA Consulting; Roche/Genentech; Sanofi; SERVIER; Xbiotech
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Bayer; Bristol-Myers Squibb; Guardant Health; HalioDX; MSD Oncology; Mundipharma; Roche/Genentech; SERVIER
Travel, Accommodations, Expenses - Amgen; Bristol-Myers Squibb; MSD Oncology; MSD Oncology; Roche/Genentech
 
Anne Hulin
No Relationships to Disclose